CLAIMS

1. A pharmaceutical composition comprising a nanoparticle composition, a botulinum toxin, ~~known therapeutic agent or independently active biologically active agent~~ and at least one excipient,

wherein the nanoparticle composition comprises a population of particles, wherein the majority of particles have diameters between 10 and 300 nanometers,

wherein the nanoparticle composition comprises at least one aqueous dispersion medium, at least one oil, and at least one surfactant,

wherein the oil is a medium chain triglyceride,

wherein the surfactant is a polysorbate,

wherein the ratio of oil to surfactant is between about 0.5:1 to about 1:1; and,

wherein the at least one excipient is mineral oil, isopropyl myristate, white petrolatum, emulsifying wax, propyl paraben, methyparaben, or any combination thereof,

wherein the pharmaceutical composition has a degree of transdermal penetration higher than when said at least one excipient is absent.

2. The pharmaceutical composition of claim 1, wherein the medium chain triglyceride is an acid containing 6-12 carbons atoms or is Labracfac Lipophile WL 1349 oil.

3. The pharmaceutical composition of claim 1, wherein the polysorbate is polysorbate 80.

4. The pharmaceutical composition of any one of claims 1-3, wherein the pharmaceutical composition does not contain parabens.

5. The pharmaceutical composition of any one of claims 1-4, wherein the known therapeutic agent or independently active biologically active agent is a protein or, ~~an antibody,~~ a protein complex ~~or a combination thereof, or wherein the known therapeutic agent or independently active biologically active agent is botulinum toxin~~.

6. The pharmaceutical composition of claim ~~5~~1, wherein the botulinum toxin is selected from the group comprising type A, type Ab, type Af, type B, type Bf, type C1, type C2, type D, type E, type F, type G, and any combinations thereof, optionally the botulinum toxin is type A botulinum toxin.

14. The use of claim 12, wherein the pharmaceutical composition is to be administered via a route of delivery selected from the group consisting of intratracheal instillation, bronchial instillation, inhalation, and combinations thereof.

15. Use of the pharmaceutical composition of any one of claims 1-6 for treating a cosmetic condition selected from the group consisting of facial wrinkles, wrinkles involving the forehead, glabellar, rhytids and/or periorbital regions, unsightly facial expressions, neck lines, hyperfunctional facial lines, hyperkinetic facial lines, and platysma bands.

16. The use of claim 12, wherein the pharmaceutical composition is to be administered via a sterile injectable formulation for parenteral administration; wherein the pharmaceutical composition is disposed within a device comprising one or a plurality of needles.

17. The use of claim 16, wherein the device comprises a plurality of needles.

18. The use of claim 17, wherein the needles have a length sufficient to project through the stratum corneum of the skin.

19. The use of claim 16, wherein the device limits effective penetration length of the one or plurality of needles into the skin.

20. The use of claim 19, wherein the effective penetration length is selected so that the one or plurality of needles does not rupture a blood vessel.

21. The use of claim 16, wherein the device is or comprises a syringe.